In February 2015, Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-menopaus
Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie whi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.